KR102601614B1 - A composition comprising Aster yomena callus culture medium as an effective element for preventing hair loss and promoting hair growth - Google Patents

Abstract

The present invention is a composition for external use that prevents hair loss and promotes hair growth, containing callus culture medium as an active ingredient. In addition, it is an external composition that prevents hair loss and promotes hair growth, further comprising niacinamide, panthenol, biotin, and menthol.

Description

A composition for external use for preventing hair loss and promoting hair growth containing the culture medium of Aster yomena callus as an effective ingredient {A composition comprising Aster yomena callus culture medium as an effective element for preventing hair loss and promoting hair growth}

The present invention relates to a composition for external use that prevents hair loss and promotes hair growth. This invention is the result of a research project, and the research project information is as follows.

Project number: P0006185, Ministry name: Ministry of Trade, Industry and Energy

Name of project management specialist organization: Jeju Regional Project Evaluation Team

Research project name: Metropolitan cooperation industry development project (region-led R&D)

Research project name: Development of premium beauty cosmetic products using natural specialized resources

Name of project carrying out organization: General Bio Co., Ltd. / Participating organization: Korea Research Institute of Bioscience and Biotechnology

Research period: 2018.10.01~2021.03.31

Alopecia is a relatively common disease that begins in adults after puberty. As living standards improve and social interest in skin care increases, interest in its treatment and prevention is gradually increasing.

The causes of hair loss are known to include genetic factors, poor diet, stress, seborrheic dandruff, and endocrine abnormalities. Topical products used for the purpose of alleviating hair loss symptoms are functional cosmetics and are approved by the Ministry of Food and Drug Safety after reviewing the safety and efficacy of each item. .

Androgenic alopecia, which is caused by male hormones and genetics, occurs in approximately 50% of both men and women, and generally begins in the 40s or 50s, but in severe cases, it begins immediately after puberty and can last for decades. For both men and women, hair loss mainly starts in the parietal region and gradually progresses to the entire head. In men, receding hair lines on both sides of the head and hair loss predominates in the parietal region, and in women, the boundary line of hair on the facial scalp is It is generally well preserved, and it is common to have a Christmas tree shape, and it is rare for a complete bald spot to form.

Products that reduce male hormones, which are known to cause hair loss, have been developed and are expected to be effective in treating hair loss. However, due to imbalance in the enhancement properties in the body, side effects such as allergies, depression, and local inflammation occur, and the risk of their application is increasing. In addition, in the case of drug therapy, the effect on the scalp area where hair growth is most needed does not reach the expected level. Therefore, there is an urgent need for the development of hair growth promotion and hair loss prevention products that are not only safe and effective for the living body, but also stable and economical in manufacturing.

Prior art documents include Korea Patent Publication No. 10-1229762, ‘Composition for external use for promoting hair growth and hair loss prevention,’ and Korea Patent Publication No. 10-1445967, ‘Hair loss prevention containing mistletoe extract and cypress extract as active ingredients. and 'shampoo composition for hair growth promotion' are described.

Republic of Korea Patent Publication No. 10-1229762 (registered on January 30, 2013) Republic of Korea Patent Publication No. 10-1445967 (registered on September 23, 2014)

The problem is to provide a composition for external use that prevents hair loss and promotes hair growth.

The solution is an external composition that prevents hair loss and promotes hair growth, containing the culture fluid of Aster callus as an active ingredient. In addition, it is an external composition that prevents hair loss and promotes hair growth, characterized in that it additionally contains niacinamide, panthenol, biotin, and menthol.

It was confirmed that the composition according to the present invention has the effect of preventing hair loss and promoting hair growth through human application tests.

Figures 1 to 7 are diagrams showing the results of human application tests in graphs or photographs.

Terms or words used in this specification and claims should not be construed as limited to their ordinary or dictionary meanings, and the inventor should use the terms and concepts of the invention in the best possible way to explain them in accordance with the technical idea of the invention. It must be interpreted as written based on meaning and concept.

Accordingly, the present invention is not limited to the presented embodiments, and the equivalent scope of the technical idea of the present invention and the technical idea described in the patent claims below can be recognized by those skilled in the art to which the present invention pertains. Various modifications and changes are possible within.

Although the present invention has been described with a focus on preferred embodiments with reference to the accompanying drawings, it is clear to those skilled in the art that various modifications can be made without departing from the technical scope of this description. Accordingly, the scope of the present invention may include many such modifications.

Example. A composition for external use that prevents hair loss and promotes hair growth

The composition for preventing hair loss and promoting hair growth according to the present invention contains a culture medium of Aster callus as a main active ingredient. Additionally, it additionally contains niacinamide, panthenol, biotin, and menthol. The composition according to the present invention can be used in tonic, shampoo, and foam products, and can be used in all other products applied to the hair and scalp.

Additionally, the composition for preventing hair loss and promoting hair growth according to the present invention may include all of the ingredients listed in Table 1 below.

Ingredients and Dosage Purified water: 47.75%, Ethanol: 23.75%,
Culture medium of Aster callus
(Aster Yomena Callus Conditioned Media): 20.58%,
Methylpropanediol: 3%,
Dipropylene Glycol: 1.167%,
Glycereth-25PCA Isostearate
(Glycereth-25 PCA Isostearate): 0.8%,
1,2-Hexanediol: 0.453%,
Hydroxyacetophenone (Hydroxyacetophenone): 0.402%,
Niacinamide: 0.3%,
Hydrolyzed Ginseng Saponins:
0.25%, Panthenol: 0.25%,
Betaine Salicylate: 0.2%,
Tromethamine (Betaine Salicylate): 0.18%,
Butylene Glycol: 0.15%,
Menthol: 0.1%,
Pinus Sylvestris Leaf Oil: 0.1%,
Aminolevulinic Acid HCL
(Aminolevulinic Acid HCl): 0.1%,
Biotin: 0.05%, Propanediol: 0.048%,
Caprylyl Glycol: 0.04%,
Winter cherry root extract
(Withania Somnifera Root Extract): 0.039%,
Acacia Concinna Fruit Extract: 0.039%,
Acacia Concinna Fruit Extract: 0.039%,
Indian gooseberry fruit extract
(Acacia Concinna Fruit Extract): 0.039%,
Hawthorn root extract
(Polygonum Multiflorum Root Extract): 0.039%,
Houttuynia Cordata Extract: 0.039%,
Turmeric root extract
(Curcuma Longa (Turmeric) Root Extract): 0.039%,
Curcuma Longa (Turmeric) Root Extract: 0.039%,
Ziziphus Joazeiro Bark Extract: 0.0065%,
Copper Tripeptide-1: 0.0005%,
Hexapeptide-2: 0.001%,
SH-Oligopeptide-1 (sh-Oligopeptide-1): 0.000005%,
SH-Polypeptide-1 (sh-Polypeptide-1): 0.000001%

Table 1 above is an example of a scalp tonic, and these ingredients can also be used in products in the form of shampoo and foam. In this case, of course, ingredients necessary for the product formulation can be added and the dosage of each ingredient can be partially adjusted.

Test example. Human application test

The following is a summary of the results obtained by requesting an example according to the present invention to a human application testing agency.

1) Exam outline

This is a test to evaluate the safety and effectiveness of "CareCella Nadimo Scalp Tonic (Test Group)" in alleviating hair loss symptoms. This is a study targeting people with hair loss symptoms, and the efficacy and effectiveness in alleviating hair loss symptoms over a total period of 24 weeks. Safety was evaluated through double-blind, controlled sample, randomized human trials.

2) Test method

Samples from the test and control groups were used, and the number of people tested was 41, with 21 people using the test group samples and 20 people using the control group samples. An appropriate amount was sprayed on the scalp twice every morning and evening and applied as if massaging.

3) Test group and control group

test group control group ingredient Purified water: 47.75% ,
Ethanol: 23.75%,
Culture medium of Aster callus: 20.58%,
Methylpropanediol: 3%,
Dipropylene glycol: 1.167%,
Glycereth-25PCA isostearate: 0.8%,
1,2-hexanediol: 0.453%,
Hydroxyacetophenone: 0.402%,
Niacinamide: 0.3%,
Hydrolyzed ginseng saponin: 0.25%,
Panthenol: 0.25%,
Betaine salicylate: 0.2%,
Tromethamine: 0.18%,
Butylene glycol: 0.15%,
Menthol: 0.1%,
Kuju pine leaf oil: 0.1%,
Aminolevulinic Acid HCL: 0.1%,
Biotin: 0.05%,
Propanediol: 0.048%,
Caprylyl glycol: 0.04%,
Winter cherry root extract: 0.039%,
Shikakai fruit extract: 0.039%,
Neem leaf extract: 0.039%,
Indian gooseberry fruit extract: 0.039%,
Hawthorn root extract: 0.039%,
Medicinal buckwheat extract: 0.039%,
Turmeric root extract: 0.039%,
Centella asiatica extract: 0.039%,
Jua bark extract: 0.0065%,
Copper tripeptide-1: 0.0005%,
Hexapeptide-2: 0.001%,
SH-Oligopeptide-1: 0.000005%,
SH-polypeptide-1: 0.000001%
Purified water: 68.33%,
Ethanol: 23.75%;

Methylpropanediol: 3%,
Dipropylene glycol: 1.167%,
Glycereth-25PCA isostearate: 0.8%,
1,2-hexanediol: 0.453%,
Hydroxyacetophenone: 0.402%,
Niacinamide: 0.3%,
Hydrolyzed ginseng saponin: 0.25%,
Panthenol: 0.25%,
Betaine salicylate: 0.2%,
Tromethamine: 0.18%;
Butylene glycol: 0.15%,
Menthol: 0.1%,
Kuju pine leaf oil: 0.1%,
Aminolevulinic Acid HCL: 0.1%,
Biotin: 0.05%,
Propanediol: 0.048%,
Caprylyl glycol: 0.04%,
Winter cherry root extract: 0.039%,
Shikakai fruit extract: 0.039%,
Neem leaf extract: 0.039%,
Indian gooseberry fruit extract: 0.039%,
Hawthorn root extract: 0.039%,
Medicinal buckwheat extract: 0.039%,
Turmeric root extract: 0.039%,
Centella asiatica extract: 0.039%,
Jua bark extract: 0.0065%,
Copper tripeptide-1: 0.0005%,
Hexapeptide-2: 0.001%,
SH-oligopeptide-1: 0.000005%,
SH-polypeptide-1: 0.000001%

4) Criteria for selecting test subjects

- Male and female test subjects diagnosed with androgenetic alopecia aged 18 to 54 years

- Male subjects diagnosed as 2 or 2A or higher according to the Norwood Hamiton classification, female subjects diagnosed as 1 or higher according to the Ludwig classification

- Subjects who will not use special hair products or hair care or manipulation during the study period

- Subjects who will maintain the same hairstyle and color as at the first visit during the study period

- Subjects who understand the purpose of this test and agree in writing to the consent form.

5) Evaluation method

a. Hair Count Analysis Using Folliscope Phototrichogram

After cutting the hair in the hair loss area to be evaluated, tattoo a small dot with a diameter of 1 mm or record certain coordinates and perform a phototricogram centered on the dot tattoo or certain coordinates each time. Total hair counts (number/cm ² ) Number of hairs in 1 cm ² circle

b. Subject evaluation by taking photos

Photographing the human body: Using a high-resolution digital camera (DSLR), take pictures of the same area at 45 degrees (frontal line) and 90 degrees (top of head) under the same conditions, composition, and location at each evaluation time, and compare before and after using the test sample. do.

Photo evaluation: Visual evaluation is conducted by two researchers on a 7-level scale, and the average of the two visual evaluation results is used as the validity evaluation variable.

c. Visual evaluation by a dermatologist

d. Subjective evaluation by test subject

e. Safety evaluation by dermatologists

6) Summary of test results

In the test area of the test group where test group samples were used for a total of 24 weeks, the number of hairs (N/cm2), the primary efficacy evaluation indicator, increased to a statistically significant level (p<005) from 8 weeks after the test compared to before the test. In addition, as a result of comparing and contrasting the hair count between groups, the interaction analysis comparing the weekly hair count change pattern between groups showed a statistically significant difference (p<005) in the weekly change pattern between the test group and the control group hair count. It was confirmed that there was a statistically significant difference (p<005) in the amount of change in hair count between the test group and the control group after 8 weeks in the comparison of the amount of change in hair count. Therefore, it is judged that the test sample used in this test helps alleviate hair loss symptoms.

7) Test results

Figures 1 to 7 are diagrams showing the results of human application tests in graphs or photographs.

7-1) Basic information and statistical values of research subjects

Number of planned study subjects 42 people Number of study subjects who drop out 1 person Number of subjects in ongoing research 41 people gender Male: 3 people Female: 38 people average age 47 years old Age distribution 30s 5 people 40s 23 people 50s 13 people

7-2) Test progress status

Week 8 Week 16 Week 24 Test group 22 people Test group 21 people Test group 21 people 20 control group 20 control group 20 control group (42 people completed) (41 people completed) (41 people completed)

7-3) Primary effectiveness evaluation - Hair count (Figure 1: Weekly hair count, Figure 2: Hair count improvement rate, Figure 4: Photographs of some of the test group subjects, Figure 5: Photos of some of the control group subjects, Figure 6: Test Folliscope Phtotrichogram of some of the group subjects, Figure 7: Folliscope Phtotrichogram of some of the control subjects)

division 0 weeks Week 8* Week 16* Week 24* test group 61.43±6.40 62.14±6.25 62.52±6.18 62.67±6.62 control group 57.60±7.11 56.45±7.84 56.10±7.94 55.65±8.25

[Average hair count (N/㎠) change pattern]

division average Standard Deviation N R.J. p-value Geonjeong test group before exam 61.43 6.40 21 0.976 >0.100 normal distribution Week 8 62.14 6.25 21 0.982 >0.100 normal distribution Week 16 62.52 6.18 21 0.986 >0.100 normal distribution Week 24 62.67 6.62 21 0.976 >0.100 normal distribution control group before exam 57.60 7.11 20 0.993 >0.100 normal distribution Week 8 56.45 7.84 20 0.990 >0.100 normal distribution Week 16 56.10 7.94 20 0.989 >0.100 normal distribution Week 24 55.65 8.25 20 0.990 >0.100 normal distribution

[Hair count (N/㎠) measurement value normality test, Ryan-Joiner Normality Test]

division average degree of freedom of difference
estimate t-value p-value test group control group Hair count before test 61.43 57.60 38 3.83 1.81 0.078

[Check homogeneity before testing hair count (N/㎠) measurements, Welch's t-test]

As a result of checking the normality of the hair count (N/cm2) measurement results, it was possible to estimate the normality of all measurement values. In addition, before starting the test, the homogeneity of the number of hairs in the test group and the control group was confirmed, and it was confirmed that there was no statistically significant difference (p<0.05) in the number of hairs between the two groups. Therefore, comparisons between the test group and control group hair count measurements before and after the test and between groups were parametrically analyzed using repeated measures analysis of variance.

division degree of freedom Adj. SS Adj. M.S. F-value p-value hair count
(N/㎠) test group 3 19.33 6.44 16.69 <0.001 control group 3 41.70 13.90 10.96 <0.001

[Hair count (N/㎠) comparison statistics before and after measurement, repeated measures analysis of variance]

division Grouping information* before exam Week 8 Week 16 Week 24 Test group hair count A B B,C C Control group hair count A B B B

[Hair count (N/㎠) measurement value statistics, post hoc test (Tukey)]

(*Means that do not share a letter have statistically significant (p <0.05) differences)

As a result of analyzing the degree of change in the hair count (N/cm2) measurement results before and after the test, the number of hairs in the test group increased at a statistically significant level (p<0.05) from the 8th week compared to before the test. These results were confirmed to be significant through a post hoc test (Tukey).

factor degree of freedom Adj. SS Adj. M.S. F-value p-value hair count Group One 1350.27 1350.27 6.78 0.013 interaction
(Group * week) 3 58.94 19.65 24.08 <0.001

[Hair count (N/㎠) comparison and contrast statistics between groups, repeated measures analysis of variance]

In order to confirm differences between groups in hair count (N/cm2) measurement results, repeated measures analysis of variance was used to verify whether there was a significant difference between groups in weekly hair counts. As a result of the analysis, a statistically significant level (p<005) difference was confirmed in the inter-group analysis comparing the weekly hair count change pattern of the test group and the control group.

division average Standard Deviation N R.J. p-value black test group Change in week 8 (△) 0.71 0.64 21 1.000 >0.100 normal distribution Change in week 16 (△) 1.10 1.14 21 0.979 >0.100 normal distribution Change at week 24 (△) 1.24 0.83 21 0.999 >0.100 normal distribution control group Change in week 8 (△) -1.15 1.73 20 0.923 <0.010 Normality rejected Change in week 16 (△) -1.50 1.88 20 0.954 0.071 normal distribution Change at week 24 (△) -1.95 2.37 20 0.905 <0.010 Normality rejected

[Test for normality of change (△) in the measured value of hair count (N/㎠) at each time point,

Ryan-Joiner Normality Test]

division average degree of freedom of difference
estimate t-value p-value test group control group 16th change (△) 1.10 -1.50 30 2.60 5.32 <0.001

[Statistical analysis between groups of change in hair count (N/㎠) measurement value (△) at each time point, Welch's t-test]

division median of difference
point estimate W p-value test group control group Change in week 8 (△) 1.00 -0.50 1.00 611.00 <0.001 Change at week 24 (△) 1.00 -1.50 3.00 636.00 <0.001

[Statistical analysis between groups of change in hair count (N/㎠) measurement value (△) at each time point,

Mann-Whitney U test]

As a result of conducting additional statistical analysis between groups to test the statistical significance between the test group and the control group in the amount of change (△) in the hair count measurement value at each time point, the change between the test group and the control group at all 8 weeks, 16 weeks, and 24 weeks was statistically significant. It was confirmed that there was a difference at a significant level (p<0.05).

In summary, as a result of analyzing the initial value homogeneity between the test group that will use the test sample before the test and the control group that will use the control sample, no statistically significant difference (p<0.05) between the groups could be confirmed, so the test group and homogeneity between the control groups could be confirmed. As a result of analyzing the degree of change before and after the test by measuring the number of hairs (N/cm2) using a phototrichogram, the number of hairs in the test group increased at a statistically significant level (p<0.05) from the 8th week. In addition, as a result of checking the differences between groups, in the inter-group analysis comparing the weekly changes in hair count, it was confirmed that there was a statistically significant difference (p<0.05) between the weekly changes in the test and control group hair counts. , in comparing the amount of change in hair count by week, it was confirmed that there was a statistically significant difference (p<0.05) in the amount of change in hair count between the test group and the control group after 8 weeks.

7-4) Secondary effectiveness evaluation - visual evaluation by the tester (Figure 3)

division Week 8 Week 16 Week 24 test group 0.05±0.22 0.05±0.22 0.14±0.48 control group 0.00±0.00 0.00±0.00 -0.05±0.22

[Change in the average score of the tester’s visual evaluation of the degree of hair improvement]

(3: very much better, 2: better, 1: slightly better,

0: No change, -1: Slightly worse, -2: Worse, -3: Very worse)

As a result of analyzing the degree of change in the examiner's visual evaluation score before and after the test, no statistically significant difference (p<0.05) could be confirmed in both the test and control groups. As a result of comparing trends between groups, no statistically significant difference (p<0.05) was found between the test group and the control group.

7-5) Secondary effectiveness evaluation - test subject questionnaire evaluation

Evaluation items Degree of improvement test group control group Week 8 Week 16 Week 24 Week 8 Week 16 Week 24 hair
enriched much better 2(9.5%) 2(9.5%) 3(14.3%) 1(5.0%) 0(0%) 0(0%) getting better 2(9.5%) 7(33.3%) 10(47.6%) 1(5.0%) 2(10.0%) 0(0%) a little better 13(61.9%) 11(52.4%) 7(33.3%) 10(50.0%) 5(25.0%) 6(30.0%) no change 3(14.3%) 0(0%) 1(4.8%) 8(40.0%) 11(55.0%) 14(70.0%) a little worse 1(4.8%) 1(4.8%) 0(0%) 0(0%) 2(10.0%) 0(0%) It gets worse 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) very bad 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) average score 1.05 1.43 1.71 0.75 0.35 0.30 Standard Deviation 0.92 0.87 0.78 0.79 0.81 0.47 leaving out
hair count
decrease much better 1(5.0%) 0(0%) 2(9.5%) 1(5.0%) 0(0%) 0(0%) getting better 3(15.0%) 7(33.3%) 11(52.4%) 2(10.0%) 2(10.0%) 0(0%) a little better 9(45.0%) 8(38.1%) 6(28.6%) 10(50.0%) 6(30.0%) 6(30.0%) no change 7(35.0%) 5(23.8%) 2(9.5%) 7(35.0%) 10(50.0%) 12(60.0%) a little worse 0(0%) 1(4.8%) 0(0%) 0(0%) 2(10.0%) 2(10.0%) It gets worse 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) very bad 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) average score 0.71 1.00 1.62 0.85 0.40 0.20 Standard Deviation 1.19 0.89 0.80 0.81 0.82 0.62 bangs line
getting better much better 1(4.8%) 1(4.8%) 1(4.8%) 0(0%) 0(0%) 0(0%) getting better 4(19.0%) 6(28.6%) 9(42.9%) 1(5.0%) 1(5.0%) 0(0%) a little better 7(33.3%) 8(38.1%) 9(42.9%) 9(45.0%) 3(15.0%) 4(20.0%) No change 8(38.1%) 5(23.8%) 2(9.5%) 10(50.0%) 15(75.0%) 16(80.0%) a little worse 0(0%) 1(4.8%) 0(0%) 0(0%) 1(5.0%) 0(0%) It gets worse 1(4.8%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) very bad 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) 0(0%) average score 0.76 1.05 1.43 0.55 0.20 0.20 Standard Deviation 1.09 0.97 0.75 0.60 0.62 0.41

[Summary of test subject survey evaluation]

The improvement evaluation score based on the survey of research subjects was evaluated in terms of the abundance of crown hair, the degree of hair loss, and the improvement of the frontal hairline. In the case of the test group, as a result of the study subjects' evaluation, statistically significant (p<0.05) improved changes were confirmed from week 24 in all indicators. In the case of the control group, statistically significant changes (p<0.05) were observed in the improvement of hair abundance and hair loss from the 24th week, and in the improvement of the frontal hairline from the 16th week, but the visual evaluation score tended to decrease. It seemed. As a result of checking the pattern of change between groups, a statistically significant level (p<0.05) difference was confirmed in the evaluation scores for both the test group and the control group, and the results confirmed through statistical analysis between groups at each time point also showed the abundance of hair and the degree of hair loss. In both the frontal line improvement items, statistically significant differences (p<0.05) were confirmed between the 16th and 24th weeks.

So far, the present invention has been examined with a focus on preferred embodiments.

The embodiments described in this specification and the configurations shown in the drawings are related to one of the most preferred embodiments of the present invention, and do not represent the entire technical idea of the present invention, so various equivalents and modifications can be used to replace them. It should be understood that there may be examples.

Therefore, the present invention is not limited to the presented embodiments, and is within the equivalent scope of the technical idea of the present invention and the technical idea described in the patent claims below, as will be recognized by those skilled in the art to which the present invention pertains. There may be embodiments in which various modifications and changes are possible.

Claims (4)

A composition for external use for preventing hair loss and promoting hair growth, comprising culture fluid of Aster callus as an active ingredient. In claim 1,
A composition for external application for preventing hair loss and promoting hair growth, characterized in that it additionally contains niacinamide, panthenol, biotin and menthol. In claim 2,
An external composition for preventing hair loss and promoting hair growth, characterized in that it contains 20.58 parts by weight of the callus culture medium, 0.3 parts by weight of niacinamide, 0.25 parts by weight of panthenol, 0.05 parts by weight of biotin, and 0.1 part by weight of menthol. In claim 2,
Methylpropanediol, dipropylene glycol, glycereth-25PCA isostearate, 1,2-hexanediol, hydroxyacetophenone, hydrolyzed ginseng saponin, betaine salicylate, tromethamine, Butylene glycol, Kuju pine leaf oil, Aminolevulinic Acid HCL, propanediol, caprylyl glycol, winter cherry root extract, Shikakai fruit extract, neem leaf extract, Indian gooseberry fruit extract, Haushu root extract, Hair loss, characterized in that it further comprises medicinal wheat extract, turmeric root extract, centella asiatica extract, jua bark extract, copper tripeptide-1, hexapeptide-2, SH-oligopeptide-1 and SH-polypeptide-1. A composition for external use for prevention and hair growth promotion.